Orbital Cellular Angiofibroma: One of the Rarest Tumor in Pandora’s Box

Authors

  • Soma Rani Roy Consultant and Head of Oculoplastic, Department of Oculoplastic and Ocular Oncology, Chittagong Eye Infirmary, Chattogram, Bangladesh
  • Rahat Anjum
  • Sujit Kumar Biswas
  • Fahmida Huque
  • Md. Sazzad Kader

DOI:

https://doi.org/10.37591/rrjooh.v12i2.3268

Keywords:

Cellular angiofibroma, orbital tumor, extragenital lesion, immunohistochemistry, surgical resection

Abstract

Orbital cellular angiofibroma is one of the rarest benign mesenchymal tumors and only two cases have been reported. It typically originates from the lower reproductive tract and does not show a gender or race preference. Total surgical resection is the suggested modality of treatment. Diagnosing tumors in rare anatomical locations can pose considerable challenges, especially when they share common histopathological characteristics with more common tumors. In such cases, achieving an accurate diagnosis often demands a meticulous approach involving comprehensive histopathological analysis and immunohistochemistry. Our reported case involves a young female, underscoring the significance of maintaining a high index of suspicion when encountering unusual clinical presentations. To effectively diagnose a rare tumor in an atypical location, it is imperative to conduct thorough clinical assessments, utilize advanced radiological imaging techniques, and employ precise histopathological analyses. This multidisciplinary approach is essential for achieving a precise diagnosis, enabling the development of tailored treatment strategies, and ultimately improving patient outcomes.

References

Hötte GJ, Verdijk RM, Gardeniers M, Paridaens D. Cellular angiofibroma of the orbit. Orbit. 2021 Jul 4; 40(4): 329–32.

Mandato VD, Santagni S, Cavazza A, Aguzzoli L, Abrate M, La Sala GB. Cellular angiofibroma in women: a review of the literature. Diagn Pathol. 2015 Dec; 10(1): 114.

Nucci MR, Granter SR, Fletcher CD. Cellular angiofibroma: a benign neoplasm distinct from angiomyofibroblastoma and spindle cell lipoma. Am J Surg Pathol. 1997 Jun 1; 21(6): 636–44.

Fletcher Christopher DM, Krishnan Unni K, Fredrik Mertens, editors. Pathology and genetics of tumours of soft tissue and bone. Vol. 4. IARC; 2002.

Firat C, Danyeli AE, Olgun Y, Sarioglu S. Cellular Angiofibroma: A Rare Tumor Behind the Ear. Int J Pediatr Res. 2022; 8: 131. doi.org/10.23937/2469-5807/151013

Das J, Das N. Cellular angiofibroma of orbit- a rare tumor at the rarest location. Orbit. 2022 Apr; 41(2): 245–249. doi: 10.1080/01676830.2020.1826986. Epub 2020 Oct 3. PMID: 33016164.

Iwasa Y, Fletcher CD. Cellular angiofibroma: clinicopathologic and immunohistochemical analysis of 51 cases. Am J Surg Pathol. 2004 Nov 1; 28(11): 1426–35. doi:10.1097/01.

Bloom J, Jordan E, Baratta VM, Zhang X, Saha A, Yavorek G, Kurbatov V. Cellular Angiofibroma Presenting as a Subepithelial Rectal Mass. ACG Case Rep J. 2020 Nov; 7(11): e00471. doi: 10.14309/crj.0000000000000471.

Liu Y, Xu Y, Wang Q, et al. Cellular angiofibroma in the hypopharynx: a case report. Medicine (Baltimore). 2019; 98(50): e18385. doi:10.1097/MD.0000000000018385.

Flucke U, Van Krieken JH, Mentzel T. Cellular angiofibroma: analysis of 25 cases emphasizing its relationship to spindle cell lipoma and mammary-type myofibroblastoma. Mod Pathol. 2011 Jan 1; 24(1): 82–9.

Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives. Pathologica. 2021 Apr; 113(2): 70–84. doi: 10.32074/1591-951X-213. Epub 2020 Nov 3. PMID: 33179614; PMCID: PMC8167394.

Downloads

Published

2023-10-16

Issue

Vol. 12 No. 2 (2023)

Section

Case Study

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.